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STUDY QUESTION: Can pharma drug discovery approaches be utilized to transform investigation into novel therapeutics for male
infertility?
SUMMARY ANSWER: High-throughput screening (HTS) is a viable approach to much-needed drug discovery for male factor infertility.
WHAT IS KNOWN ALREADY: There is both huge demand and a genuine clinical need for new treatment options for infertile men.
However, the time, effort and resources required for drug discovery are currently exorbitant, due to the unique challenges of the cellular,
physical and functional properties of human spermatozoa and a lack of appropriate assay platform.
STUDY DESIGN, SIZE, DURATION: Spermatozoa were obtained from healthy volunteer research donors and subfertile patients
undergoing IVF/ICSI at a hospital-assisted reproductive techniques clinic between January 2012 and November 2016.
PARTICIPANTS/MATERIALS, SETTING, METHODS: A HTS assay was developed and validated using intracellular calcium ([Ca2+]i)
as a surrogate for motility in human spermatozoa. Calcium ﬂuorescence was detected using a Flexstation microplate reader (384-well plat-
form) and compared with responses evoked by progesterone, a compound known to modify a number of biologically relevant behaviours in
human spermatozoa. Hit compounds identiﬁed following single point drug screen (10 μM) of an ion channel-focussed library assembled by
the University of Dundee Drug Discovery Unit were rescreened to ensure potency using standard 10 point half-logarithm concentration
curves, and tested for purity and integrity using liquid chromatography and mass spectrometry. Hit compounds were grouped by structure
activity relationships and ﬁve representative compounds then further investigated for direct effects on spermatozoa, using computer-assisted
sperm assessment, sperm penetration assay and whole-cell patch clamping.
MAIN RESULTS AND THE ROLE OF CHANCE: Of the 3242 ion channel library ligands screened, 384 compounds (11.8%) elicited a
statistically signiﬁcant increase in calcium ﬂuorescence, with greater than 3× median absolute deviation above the baseline. Seventy-four com-
pounds eliciting ≥50% increase in ﬂuorescence in the primary screen were rescreened and evaluated further, resulting in 48 hit compounds
that produced a concentration-dependent increase in [Ca2+]i. Sperm penetration studies conﬁrmed in vitro exposure to two hit compounds
(A and B) resulted in signiﬁcant improvement in functional motility in spermatozoa from healthy volunteer donors (A: 1 cm penetration index
2.54, 2 cm penetration index 2.49; P < 0.005 and B: 1 cm penetration index 2.1, 2 cm penetration index 2.6; P < 0.005), but crucially, also in
patient samples from those undergoing fertility treatment (A: 1 cm penetration index 2.4; P = 0.009, 2 cm penetration index 3.6; P = 0.02
and B: 1 cm penetration index 2.2; P = 0.0004, 2 cm penetration index 3.6; P = 0.002). This was primarily as a result of direct or indirect
CatSper channel action, supported by evidence from electrophysiology studies of individual sperm.
LIMITATIONS, REASONS FOR CAUTION: Increase and ﬂuxes in [Ca2+]i are fundamental to the regulation of sperm motility and function,
including acrosome reaction. The use of calcium signalling as a surrogate for sperm motility is acknowledged as a potential limitation in this study.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
WIDER IMPLICATIONS OF THE FINDINGS:We conclude that HTS can robustly, efﬁciently, identify novel compounds that increase
[Ca2+]i in human spermatozoa and functionally modify motility, and propose its use as a cornerstone to build and transform much-needed
drug discovery for male infertility.
STUDY FUNDING/COMPETING INTEREST(S): The majority of the data were obtained using funding from TENOVUS Scotland and
Chief Scientist Ofﬁce NRS Fellowship. Additional funding was provided by NHS Tayside, MRC project grants (MR/K013343/1, MR/012492/1)
and University of Abertay. The authors declare that there is no conﬂict of interest.
TRAIL REGISTRATION NUMBER: N/A.
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Introduction
Infertility is a signiﬁcant global problem affecting ~1 in 7, or ~80 million
couples (Slama et al., 2012; Datta et al., 2016). Although the causes of
infertility are heterogeneous, male factor is now the leading cause and
accounts for at least 50% of cases (HFEA, 2014). Asthenozoospermia
(poor/dysfunctional sperm motility) is the commonest disorder in this
population (Curi et al., 2003), yet there is no drug a man can take, nor
that can be added to his sperm in vitro, to improve fertility (Barratt et al.,
2011). Couples instead rely on Artiﬁcial Reproduction Technology
(ART), such as IVF and ICSI, which is expensive, invasive and not with-
out risk. Despite this, year-on-year, ART is increasingly utilized world-
wide (Kupka et al., 2014, 2016; Sunderam et al., 2014). There is clearly
an unmet need for the development of alternate treatment strategies
for male factor infertility, and a demand for focussed treatment options
to improve sperm motility.
Drug discovery is a lengthy, high-risk and expensive process, esti-
mated to take at least 12 years and cost upwards of $2.6 billion for
each drug to be successfully approved for clinical use (DiMasi et al.,
2016). Computational chemistry and molecular mechanics are com-
monly utilized approaches in drug discovery, and use predictive model-
ling of molecular structure and properties to artiﬁcially design potential
novel therapeutics. In the absence of a known speciﬁc molecular or
receptor target, compound library high-throughput screening (HTS) is
an alternative approach that has developed in recent decades (Miller,
2006). HTS provides an important source of hits for drug discovery
programmes (Broach and Thorner, 1996), but its success clearly relies
either on the diversity, or intended focus, of the library collection
screened, as well as the diversity screened within the deﬁned territory
of the library itself, aiming to maximize coverage of ‘lead-like chemical
space’. However, a fundamental hurdle to development of new drugs,
either for male fertility or contraceptive use, is the lack of appropriate
assay systems to allow rapid screening of large and diverse pharma
libraries (Carlson et al., 2009). The challenge of the unique size, shape
and motility of spermatozoa has instead resulted in current strategies
based on direct assessment of sperm motility and function, which is
not feasible in the context of a drug discovery programme due to the
prohibitive costs of time and resources (Tardif et al., 2014).
Sperm do not transcribe nor translate and instead rely on post-
translational modiﬁcation of proteins as primary signalling mechanisms
(Grootegoed et al., 2000). For example, cyclic AMP-dependent phos-
phorylation of ﬂagellar proteins is required for initiation and maintenance
of sperm motility (Tash and Means, 1982, 1983; San Agustin and
Witman, 1994; Visconti et al., 1997). Ion channels and ionic gradients
play key roles in orchestrating intracellular signalling pathways (Darszon
et al., 2011). Increase and ﬂuxes in intracellular calcium [Ca2+]i are funda-
mental to the regulation of sperm motility and function, including changes
in direction, hyperactivation and chemotaxis (Publicover et al., 2007;
Darszon et al., 2011) and there is a plethora of evidence that calcium
mobilization in sperm is related to fertilization in vivo and in vitro (Baldi
et al., 2009; Publicover and Barratt, 2011; Alasmari et al., 2013a,b).
[Ca2+]i is regulated by at least two processes in spermatozoa: mobil-
ization of Ca2+ stored in the acrosome and neck region (Ho and
Suarez, 2001, 2003; Ren et al., 2001; Ho et al., 2002; Quill et al., 2003;
Marquez et al., 2007) and/or transmembrane ﬂux through Ca2+ per-
meable ion channels and transporters. In mice, the main source of Ca2
+ entry appears to be via pH-dependent CatSper (Cation channel of
Sperm) channels in the plasma membrane of the ﬂagellar principal
piece. CatSper is also essential for male fertility; sperm from CatSper
knock-out mice are motile but cannot hyperactivate, rendering them
unable to migrate to or within the oviduct (Carlson et al., 2003; Ho
et al., 2009) and unable to fertilize oocytes, even by IVF (Ren et al.,
2001). Further evidence that CatSper is critical to sperm function
comes from the identiﬁcation of natural mutations affecting CatSper
gene family members (‘CatSper 1 and 2’) that are associated with oli-
goasthenoteratozoospermia (Hildebrand et al., 2010; Smith et al.,
2013). Ca2+ entry into human sperm in response to progesterone
(a product of cumulus cells) is via non-genomic activation of CatSper
channels (Lishko et al., 2011; Strunker et al., 2011; Williams et al.,
2015). CatSper activation by organic molecules that appear to evoke
chemotaxis has also been described, and it is therefore proposed that
this ion channel acts as a polymodal chemosensor that integrates mul-
tiple chemical cues from the female reproductive tract and directs
sperm towards the egg (Brenker et al., 2012). Pharmacological agents,
including direct or indirect CatSper agonists, could offer huge potential
for development of new treatments for male subfertility.
Given that calcium plays a fundamental role in sperm physiology, the
aim of this study was to develop and validate a HTS assay using a cal-
cium reporting system to allow screening of large libraries of drug dis-
covery compounds to identify potential leads that may also have a
positive functional effect on sperm motility. Following development of
a HTS assay we screened 3242 compounds from an ion channel-
focussed library. Potential leads of interest were subject to detailed
analysis, which initially involved assessment of motility responses in
donors. The compounds that showed a positive response were then
tested on a selected group of patient samples using computer-assisted
sperm assessment (CASA) and functional motility assays. Additionally,
electrophysiology was performed to examine if the selected
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compounds activated CatSper. A schematic identifying this strategy is
presented (Fig. 1).
Materials andMethods
Ethical approval
Healthy volunteer research donors with normal sperm concentration and
motility according to WHO 2010 criteria (Cooper et al., 2010) were
recruited in accordance with the Human Fertilisation and Embryology
Authority (HFEA) Code of Practice (version 8) under local ethical approval
(13/ES/0091) from East of Scotland Research Ethics Service (EoSRES)
REC 1. Under the same ethical approval, subfertile patients undertaking
treatment at Assisted Conception Unit (ACU), Ninewells Hospital, Dundee
Scotland, consented to research use of samples surplus to clinical
requirement.
Semen samples
Semen samples were collected by masturbation into a sterile plastic con-
tainer after 2–5 days of sexual abstinence. Samples were used for analysis
after liquefaction for ~30 min at 37°C, and processed within 1 h of produc-
tion. Samples were obtained and analysed in line with suggested guidance
for human semen studies (Bjorndahl et al., 2016).
Sperm preparation
All chemicals were purchased from Sigma-Aldrich, UK. Cells were prepared
by density gradient centrifugation (DGC), using non-capacitating medium
(NCM; 1.8mM CaCl2, 5.4 mM KCl, 0.8 MgSO4.7H2O, 116.4 mM NaCl,
1.0 mM Na2PO4.2H2O, 5.55mM D-Glucose, 2.73mM sodium pyruvate,
41.75 mM sodium lactate, 25mM HEPES, 0.3% bovine serum albumin
(BSA), pH 7.4)-buffered percoll. In all, ≤1.5 ml semen was added to the top
layer of the density gradient (2 ml 40% underlaid with 2 ml 80%), and then
centrifuged (300g, 20min). The pellet was washed in NCM (500 g, 10min).
Cells were then resuspended in 5 ml bicarbonate-buffered medium to sup-
port capacitation (capacitation medium (CM); 3 mM CaCl2, 4.7 mM KCl,
1.0 mM MgSO4.7H2O, 106mM NaCl, 1.5 mM Na2PO4.2H2O, 5.55mM
D-Glucose, 1.0 mM sodium pyruvate, 41.75 mM sodium lactate, 1.33mM
glycine, 0.68mM glutamine, 0.07mM taurine, 0.01mM non-essential amino
acids, 25mM sodium bicarbonate, 0.3% BSA, pH 7.4–7.6) and incubated for
2–3 h (37°C, 5% CO2). Concentration and baseline motility assessment
were performed using CASA before subjecting to experimental conditions.
Patient samples surplus to requirement for IVF treatment were also
used for analysis. Commercially available media were used for sperm prep-
aration by DGC (40%/80%), namely PureSpermTM (Nidacom, Molndal,
Sweden) diluted in Quinn’s Advantage Medium with HEPES (SAGE
In-Vitro Fertilisation, Pasadena, CA, USA). Following centrifugation (300g;
20 min), the pellet was washed by centrifugation at 500g for 10 min in 4 ml
Quinn’s Advantage Medium with HEPES. Supernatant was discarded and
the pellet resuspended in Quinn’s Advantage Fertilisation medium.
Flexstation assay
Spermatozoa from two to four different donors were pooled together after
sperm preparation in order to reliably obtain enough cells, and diluted to a
density of 2.2 × 107 cells/ml in Flexstation assay buffer (1× Hanks Buffered
Salt Solution (HBSS, Invitrogen, Waltham, MA, USA), 20mM HEPES,
0.5 mM probenecid, pH 7.4). Unless otherwise stated, an equal volume of
the calcium-sensitive dye, Calcium 3 (Molecular Devices, Sunnyvale, CA,
USA), made up to twice the manufacturer’s recommended concentration,
was added to the cells. Following incubation (37°C, 60min), the sperm cells
were recovered by centrifugation (700g, 5 min) and resuspended in
Flexstation assay buffer at a density of 5 × 106 cells/ml. Cells were plated on
384-well clear bottom, black wall assay plates (Greiner Bio One, UK) at a
density of 2.5 × 105 cells/50 μl/well. To ensure cells were restricted to the
base of each well, the plates were centrifuged (700g, 5 min) at room tem-
perature. Test compounds were prepared at a concentration of 50 μM on
384-well polypropylene plates (Greiner Bio One) as described below. The
effect of compounds on spermatozoa [Ca2+]i was measured using a
Flexstation 3 (Molecular Devices). Baseline calcium-dependent ﬂuorescence
(excitation wavelength = 485 nm, emission wavelength = 525 nm, cut-off =
515 nm) was measured for 18 s. In all, 12.5 μl of each test compound was
transferred to the assay plates using an internal 16-channel robotic pipette
head and the resulting change in ﬂuorescence monitored for a further 82 s.
Compound screening
The University of Dundee Drug Discovery Unit (DDU) ion channel library
comprises putative ion channel ligands assembled from ChEMBL database
(Mok and Brenk, 2011). In all, 3242 compounds were prepared as stock
solutions in dimethylsulphoxide (DMSO) at a concentration of 10 mM and
supplied in 384-well Echo plates (Labcyte, Sunnyvale, CA, USA) for use in
the screening campaign. In follow-up assays designed to determine the
potency of hit compounds, the compounds were dispensed into 384-well
polypropylene plates either from the compound library or from re-
purchased material re-constituted in DMSO (10 mM), using an automated
liquid handling workstation (JANUS, PerkinElmer, UK). A 3-fold serial dilu-
tion of each compound into DMSO and subsequent transfer into 384-well
Echo plates was performed using the Biomek FX automated liquid handling
workstation (Beckman Coulter, UK). Intermediate screening plates were
generated by transferring 250 nl of compound into 384-well polypropylene
Ion channel focussed library screen
n = 3242
Compounds showing significant
increase in calcium
Most potent compounds: generation of
concentration effect curves / assess
structural integrity by LC-MS
Compounds prioritised based on
calcium responses, hit confirmation
and further profiling
n = 5
Assess motility in donor cells:
CASA and functional motility
(viscous media penetration)
Assess motility in patient samples:
CASA and functional motility
(viscous media penetration)
Preliminary assessment of mode of
action: electrophysiology
assessment for CatSper and
Ksper; effect on pH
n = 384
n = 48
Figure 1 Schematic of research strategy. CASA, computer-assisted
sperm analysis; LC–MS, liquid chromatography and mass spectrom-
etry; CatSper, Cation channel of Sperm; KSper, K+ current that con-
trols sperm membrane potential.
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plates using an Echo 550 accoustic dispenser (Labcyte) and diluting 200-
fold in ﬂexstation assay buffer (50 μl). Compound testing was performed
on the Flexstation 3 as described above. All assay plates in the screen
were subject to quality control analysis. The performance of the assay on
each screening plate was also evaluated using internal controls, whereby
the maximum and minimum calcium-mediated ﬂuorescence was deter-
mined in the absence and presence of progesterone (10 μM), respectively.
Motility assessment: CASA
Following preparation, spermatozoa were subjected to capacitating condi-
tions for 2.5 h in a 5% CO2 humidiﬁed atmosphere. They were then mixed
with either DMSO (vehicle; 1% ﬁnal concentration) or compound (10 μM
ﬁnal concentration) and incubated further (37°C; 5% CO2 humidiﬁed
atmosphere). Motility was evaluated using a CASA system (CEROS
machine (version 12), Hamilton Thorne Research, Beverly, MA, USA)
attached to an external microscope at set time intervals. Sperm kinematics
were assessed under a negative phase contrast objective, using system par-
ameter settings for analyses as previously described (Tardif et al., 2014).
Spermatozoa were examined in four-chamber 20 μm deep slides (Vitrolife,
Sweden), and 800–1000 sperm cells analysed per slide.
Motility assessment: sperm penetration test
As previously described (Ivic et al., 2002), glass tubes (5 cm × 0.4 mm ×
4mm; Camlab Limited, Cambridge, UK) were loaded with methylcellulose
(4000cp; Sigma-Aldrich M0512) by capillary action. The ﬁlled tubes were
placed vertically into eppendorf tubes containing (i) 100 μl of spermatozoa
(control), (ii) 100 μl spermatozoa and 1%DMSO (vehicle control), (iii) 100 μl
spermatozoa and 3.6 μM progesterone (positive control) or (iv) 100 μl
spermatozoa and 10 μM compound, and incubated at 37°C in 5% CO2 for
1 h. Number of spermatozoa was scored at 1 and 2 cm using an Olympus
CX41 microscope (20× objective, ﬁnal magniﬁcation ×200) (Olympus
Corporation, Tokyo, Japan). Results were normalized to parallel untreated
controls to allow comparison between different experiments, and expressed
as a penetration index [number of spermatozoa observed with treatment/
number of spermatozoa without treatment (control)].
Patch-clamp electrophysiology
Electrophysiological responses of individual spermatozoa were investigated
using whole-cell recording technique as previously described (Brenker et al.,
2012; Mansell et al., 2014). Brieﬂy, gigaohm seals were formed between the
pipette and cytoplasmic droplet or midpiece of spermatozoa superfused
with standard extracellular solution containing (mM): NaCl, 135; KCl, 5;
CaCl2, 2; MgSO4, 1; HEPES, 20; Glucose, 5; Na pyruvate, 1; Lactic acid, 10;
pH adjusted to 7.4 with NaOH which brought [Na+] to 154mM. The trans-
ition to whole-cell conﬁguration was achieved by light suction. CatSper-
mediated monovalent currents (ICatSper) were recorded in sodium-based
divalent-free extracellular solution (NaDVF) containing (mM): 140 NaCl, 40
HEPES, and one EGTA adjusted to pH 7.4 with NaOH and using Cs-based
pipette solution containing (mM): Cs-methanesulphonate, 130; HEPES, 40;
Tris–HCl, 1; EGTA, 3; EDTA, 2 mM, pH adjusted to 7.4 with CsOH.
CatSper currents were evoked by successive 1 s depolarizing ramps from
−80 to 80mV from a holding potential of 0 mV.
K+ currents were recorded under quasi-physiological conditions
(Mansell et al., 2014) using standard extracellular solution and standard
pipette solution containing (mM): NaCl, 10; KCl, 18; K gluconate, 92;
MgCl2, 0.5, CaCl2, 0.6; EGTA, 1; HEPES, 10; pH was adjusted to 7.4 using
KOH which brought [K+] to 114 mM and [Ca2+] to 100 nM. K+ currents
were evoked by successive 1 s depolarizing ramps from −92 to 68 mV
(corrected for junction potential) at 1 Hz from a holding potential of
−92 mV. All data are adjusted for cell capacitance, expressed as pA/pF.
Cytoplasmic pH
Cytoplasmic pH was measured using 2′,7′-bis(2-carboxyethyl)-5,6-carboxy-
ﬂuorescein (BCECF; ThermoFisher, Paisley, UK) and a FLUOstar omega
reader (BMG Labtech, Offenburg, Germany). Donor sperm were prepared
and capacitated as described above, and then incubated with 2mM of the
acetoxymethyl (AM)-coupled dye for 45 min. Free dye was removed and
spermatozoa resuspended in assay buffer (BSA, Bicarbonate-free CM
media buffered to pH 7.4 with HEPES). Fluorescence was monitored
(excitation wavelength = 440/490 nm, emission wavelength = 530 nm)
and quenched with manganese at the end of the assay period to allow sub-
traction of background ﬂuorescence. NH4 or compound was added after
2 min. Extracellular calibration was used for cytoplasmic pH experiments;
cells were lysed with 0.1% triton at the end of the assay period to record
signal for pH 7.4. A ﬁxed volume of 3.2% HCl was then added which
reduced the pH to 6.7. As a comparator, intracellular calcium was mea-
sured using FURA2 (ThermoFisher) and FLUOstar omega reader as previ-
ously described (Williams et al., 2015). Progesterone-induced increments
in the ratio of emission intensities (excitation wavelength = 340 nm, emis-
sion wavelength = 380 nm) were used to quantify changes in [Ca2+]i
concentration.
Statistical analysis
Preliminary analysis of all HTS primary and potency raw data was per-
formed using the AUC function within the SoftMax Pro analysis software
(Molecular Devices) to quantitate agonist-evoked ﬂuorescence. The cri-
teria for data acceptance for each assay plate was based on robust statis-
tics and deﬁned as follows: (i) signal to Background ≥5 (AUCmax/AUCmin),
(ii) Coefﬁcient of Variance <12% (sMADmax/AUCmax × 100) and (iii) Z′ ≥
0.5 (1−((3 × sMADmax) + (3 × sMADmin))/(AUCmax − AUCmin)), where
AUCmax was the median calcium-mediated ﬂuorescence in the presence
of progesterone (10 µM), AUCmin was the median ﬂuorescence of all nega-
tive control signal, sMADmax = 1.4826 (median absolute deviation (MAD)
in the presence of progesterone) and sMADmin = 1.4826 (MAD in the
absence of progesterone).
Data were exported as a text ﬁle for further data processing and analysis
in Activity Base version 7.3.1.4 (IDBS) and the percentage effect for each
compound was normalized to the effect of progesterone (10 μM). All
curve ﬁtting was performed in Activity Base XE using the underlying
‘MATH IQ’ engine of XLﬁt version 5.1.0.0 from IDBS. The 4-parameter
logistic dose–response curve y = A + (B – A)/1 + (10C/x)D was utilized for
compound potency determination, where A is minimum response
(AUCmin), B is maximum response (AUCmax), C is pEC50 and D is the Hill
Slope. Potency was deﬁned by reference to the negative log Molar value at
the point of inﬂection of the sigmoidal concentration–response curve gen-
erated (pEC50). Database querying and report creation was undertaken
using Reporter version 7.3.0 from IDBS.
Statistical comparisons for CASA kinematics and viscous penetration
test (normalized against control) were made using unpaired t-tests.
Unpaired t-tests were performed on currents obtained from whole-cell
patch clamp. The statistical package Prism GraphPad (La Jolla, CA, USA)
was used. P < 0.05 was considered signiﬁcant.
Results
Flexstation assay development
A primary cell-based assay was optimized in 384-well plates, using a
Flexstation 3 microplate reader to detect calcium ﬂuorescence in motile
human spermatozoa. The effect of progesterone (3.6 μM) on cytosolic
calcium was assessed under a range of conditions. As expected, the
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calcium ﬂuorescence elicited in response to progesterone increased with
greater cell concentration (range 5000–250 000 cells in 50 μl per well;
Fig. 2A). The amplitude of the response elicited by progesterone was
also dependent upon the calcium-sensitive dye used (Fig. 2B and C), with
the largest assay window being observed with Calcium 3. A smaller assay
window was observed when cells were loaded with either Fluo3-AM,
due to lower amplitude ﬂuorescence response or Calcium 5, due to high-
er background ﬂuorescence. All further experiments were therefore per-
formed using Calcium 3. Fluorescence was measured at a range of
extracellular calcium concentrations attempting to increase the amplitude
of the evoked response, with a view to reducing cell number in the assay.
However, an inverse relationship was observed between the progester-
one response evoked and calcium concentration (Fig. 2D). Since all small
molecules in the compound library are in solution in DMSO, we also con-
ﬁrmed that the assay was able to tolerate DMSO up to a concentration
of 3% (v/v), which is in excess of the 0.1% (v/v) used in library screening
(Fig. 2E). Conditions selected for subsequent compound testing were
~250 000 motile spermatozoa per well, suspended in 50 μl assay buffer
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Figure 2 Flexstation assay development. Capacitated spermatozoa were pre-loaded with calcium-sensitive ﬂuorescent dyes and progesterone
evoked responses measured. Progesterone evoked ﬂuorescence increased with increase in sperm cell concentration (A). Calcium 3 dye had a larger
assay window compared with Fluo3-AM due to higher amplitude of ﬂuorescence (B). Calcium 3 dye had a larger assay window compared with
Calcium 5 dye, due to lower background ﬂuorescence (C). Amplitude of the progesterone evoked response was inversely proportional to the extra-
cellular calcium concentration (D). Progesterone elicited responses were unaffected by DMSO at concentrations up to 3% (v/v) (E). Progesterone
evokes a concentration-dependent increase in intracellular calcium in human sperm cells (F).
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containing 1.3 mM calcium chloride. Under these conditions, progester-
one elicited a concentration-dependent increase in [Ca2+]i in spermato-
zoa, pEC50 = 7.5 and Hill slope = 0.7 (Fig. 2F). These values are in
agreement with those obtained by direct measurement of CatSper cur-
rents using electrophysiology (Strunker et al., 2011).
Ion channel library screen
A focussed ion channel library screen was then performed using 80%
fraction spermatozoa prepared by discontinuous DGC and subjected to
capacitating conditions. Cells were pooled from multiple donors (n =
2–4 per plate). The primary assay proved to be highly reproducible
(robust Z′ = 0.8 ± 0.1) and 3242 compounds were tested at a single
concentration (10 μM). The primary screening data displayed a charac-
teristic pseudo-normal distribution (Fig. 3) and 384 compounds (11.8%)
elicited a statistically signiﬁcant increase in calcium ﬂuorescence, with
greater than 3× MAD above the baseline. However, 74 of the most
potent compounds were selected for the generation of concentration/
effect curves based on a pragmatic cut-off of 50% increase in ﬂuores-
cence. Of the 74 compounds re-tested, concentration–response curves
were returned for 67, although structural integrity was only conﬁrmed
by liquid chromatography–mass spectrometry (LC–MS) for 48. Hit com-
pounds were subsequently analysed and grouped by structure activity
relationships (SARs). To facilitate further studies, concentration–
response curves from hit compounds were visually inspected and the
compounds prioritized based on their potential to elicit calcium
response. The best agonists were coded A, B, C, D and E. These com-
pounds were from several different chemical classes and structurally dis-
tinct from progesterone, and included a tertiary amide (A), piperidine
amide (B), a secondary amide (C), thienopyrimidine (D) and quiniline
(E). These ﬁve compounds were then used for hit conﬁrmation and fur-
ther proﬁling. Activity of each compound was conﬁrmed in the ﬂexsta-
tion assay with pEC50 values between 5.3 and 5.6 and Hill slopes of
0.9–2.5 (Table I; Supplementary Fig. S1).
Motility assessment
Initial motility assessment using CASA showed no signiﬁcant improve-
ment in total motility or progressive motility, nor individual kinematics,
following addition of any compounds A–E to prepared spermatozoa
from healthy volunteer donors (Supplementary Fig. S2). However, this
was not unexpected, given the high level of motility characteristics in
almost all prepared samples. Despite representing a key part of diag-
nostic semen analysis, it is widely accepted that motility assessment is
an imperfect tool in predicting male fertility (Vasan, 2011). A sperm
penetration assay was therefore used to assess and challenge func-
tional motility of sperm, using 1% methylcellulose as viscous media
(Kremer, 1965; Ivic et al., 2002). In all, 10 μM compound A signiﬁcantly
increased cell numbers penetrated into viscous media (1 cm penetra-
tion index 2.54, 2 cm penetration index 2.49; P < 0.005). In all, 10 μM
compound B also signiﬁcantly increased cell numbers penetrated into
viscous media (1 cm penetration index 2.1, 2 cm penetration index
2.6; P < 0.005). There was no signiﬁcant increase in penetration index
with the other compounds tested (Fig. 4A).
Furthermore, a panel of patient samples (Supplementary Table S1)
exposed to 10 μM compound A (n = 8) and 10 μM compound B (n =
17) also showed a signiﬁcant increase in penetration index (A: 1 cm
penetration index 2.4; P = 0.009, 2 cm penetration index 3.6; P =
0.02; Fig. 4B and C; B: 1 cm penetration index 2.2; P = 0.0004, 2 cm
penetration index 3.6; P = 0.002; Fig. 4D and E). These samples were
surplus to clinical requirements and donated for research on the day
of IVF/ICSI, thus supporting a potential clinical application for this
compound.
Patch-clamp electrophysiology
These two compounds (A and B) were then studied in a patch-clamp
system, to assess individual human sperm responses (Mansell et al.,
2014). Monovalent CatSper currents (ICatSper) were recorded under
sodium-based divalent-free (NaDVF) conditions. As demonstrated
previously (Lishko et al., 2011; Strunker et al., 2011), progesterone sig-
niﬁcantly potentiates ICatSper (Fig. 5A and B). Similarly, these com-
pounds signiﬁcantly potentiated ICatSper (Fig. 5C–F) with no effect on
outward K+ currents (Brown et al., 2016) (Fig. 5G and H).
Cytoplasmic pH
Given that alkalinization of cytoplasmic pH is a characterized activator
for the CatSper complex, we used BCECF to track changes in
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Figure 3 Ion channel library screen. Frequency histogram for 3242
compounds tested in the primary Flexstation screen. 384 compounds
elicited a statistically signiﬁcant increase in calcium ﬂuorescence (>3
mean absolute deviation (MAD); 11.8%).
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Table I Potency of ﬁve selected hit compounds from
ion channel library screen.
Compound Lab code PEC50 Hill slope
DDD00104789 A 5.3 1.5
DDD00104960 B 5.4 1.0
DDD00105020 C 5.5 1.0
DDD00105498 D 5.6 1.3
DDD00106181 E 5.6 0.9
pEC50 and Hill slopes were determined from concentration effect curves generated
for each compound (see also Supplementary Fig. S1).
979Drug discovery for male subfertility
A0
0.5
1
1.5
2
2.5
3
3.5
4
1cm 2 cm
PENETRATION DEPTH (DONOR SAMPLES)
CONTROL
A
B
C
D
E
PROGESTERONEP
E
N
E
T
R
A
T
IO
N
 IN
D
E
X
∗
∗∗
∗
∗∗
† †
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
1cm 2cm
B
P
E
N
E
T
R
A
T
IO
N
 IN
D
E
X
PENETRATION DEPTH (PATIENT SAMPLES)
CONTROL
A
PROGESTERONE∗
∗
∗∗
∗∗
0
0.5
1
1.5
2
2.5
3
3.5
4
1cm 2cm
D
P
E
N
E
T
R
A
T
IO
N
 IN
D
E
X
PENETRATION DEPTH (PATIENT SAMPLES)
CONTROL
B
PROGESTERONE∗
∗
∗∗
∗∗
0.0
1.0
2.0
3.0
4.0
5.0
6.0C
0.0
1.0
2.0
3.0
4.0
5.0
6.0E
Figure 4 Sperm penetration assay. (A) Signiﬁcant increase in functional motility seen in spermatozoa from healthy volunteer donors exposed to
10 μM compound A (1 cm penetration index 2.54, 2 cm penetration index 2.49; †P < 0.005) and 10 μM compound B (1 cm penetration index 2.1,
2 cm penetration index 2.6; *P < 0.005). Other hit compounds elicited no increase in functional motility. 3.6 μM progesterone was used as a posi-
tive control (1 cm penetration index 2.80, 2 cm penetration index 3.36; **P < 0.005). (B) Signiﬁcant increase in functional motility seen in sperm-
atozoa from patient samples exposed to 10 μM compound A (1 cm penetration index 2.4; *P = 0.009, 2 cm penetration index 3.6; *P = 0.02).
3.6 μM progesterone was used as a positive control (1 cm penetration index 1.6; P = 0.03, 2 cm penetration index 1.9; **P = 0.001). (C) Individual
patient responses to 10 μM compound A. Control (black line) = 1. (D) Signiﬁcant increase in functional motility seen in spermatozoa from patient
samples exposed to 10μM compound B (1 cm penetration index 2.2; *P = 0.0004, 2 cm penetration index 3.6; *P = 0.002). 3.6 μM progesterone
was used as a positive control (1 cm penetration index 2.0; **P = 0.005, 2 cm penetration index 2.9; **P = 0.0005). (E) Individual patient response
to 10μM compound B. Control (black line) = 1.
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Figure 5 Patch-clamp electrophysiology. Compounds A and B selectively potentiate CatSper currents. Monovalent (NaDVF) CatSper currents
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intracellular pH following treatment with compounds A and B.
However, no effect on pH was observed (Supplementary Fig. S3).
Discussion
With the rationale that asthenozoospermia is the commonest problem
underlying male subfertility (van der Steeg et al., 2011), sperm motility is
an obvious target for development of new fertility treatments. However,
motility screening is currently impossible to interrogate efﬁciently and
accurately on a large scale, making this an unrealistic approach to drug
discovery for male subfertility (Tardif et al., 2014). Despite the theoret-
ical possibility of therapeutic manipulation to modify and improve sperm
motility, effective treatment strategies for male factor infertility remain
elusive. Nonetheless, the ability to treat motility defects in sperm could
offer a viable alternative to IVF/ICSI for a signiﬁcant cohort of patients,
resulting not only in cost savings but reduced intensity of medical inter-
vention and patient distress (van Rumste et al., 2014; Rooney and
Domar, 2016). A key limitation in the quest for new treatments for
male subfertility is the lack of detailed knowledge of the physiology and
biochemical pathways underlying sperm motility and function, and a fun-
damental lack of obvious target for drug screening. However, speciﬁc
loss of CatSper function is sufﬁcient to compromise fertilizing capacity of
human spermatozoa and is thought to represent an underlying factor in
sperm dysfunction (Williams et al., 2015). Indeed, emerging data reveal
the existence of multiple CatSper modulators, including synthetic endo-
crine disrupting chemicals (Tavares et al., 2013; Schiffer et al., 2014),
which may negatively affect male fertility by effects on sperm motility
and/or premature acrosome reaction.
This study shows that HTS can detect hit compounds with the poten-
tial to translate into identiﬁcation of novel agents with positive effects on
functional motility of sperm from subfertile patients. HTS directly exam-
ining motility effects, particularly when there is a need to rapidly screen
thousands of compounds, is currently impracticable. Our screening
approach instead focussed on a key aspect of sperm biology: modulation
of [Ca2+]i. Having ﬁrst established a HTS system, we then screened a
3242-compound ion channel-focussed library. Compounds that showed
a positive response (demonstrating changes in calcium and motility)
were subsequently tested on a selected group of patient samples using
CASA and functional motility assays. Importantly, two compounds
(A and B) showed a signiﬁcant increase in functional motility in patient
samples, thus demonstrating the potential of a HTS approach to dis-
cover novel compounds to enhance sperm function. Development of a
HTS assay requires a balance between the necessity to screen a large
number of compounds against the possibility and frequency of false posi-
tive/negative responses. Calcium was used in this screen primarily
because it is known to be important for sperm motility, but also because
it could be scaled up for HTS, as demonstrated by Schiffer and collea-
gues, who used a 384-microplate system to monitor calcium responses
in human sperm to examine the action of 96 synthetic endocrine dis-
rupting chemicals (Schiffer et al., 2014). However, whilst our data are
very promising, calcium is only a surrogate of motility and has limitations.
For example, some compounds generated an increase in calcium but no
signiﬁcant changes in functional motility. There are a number of reasons
why this may be so. One explanation would be the nature of the calcium
response examined in populations of spermatozoa over a short period
of time. In this study (as in all studies of this type), cells are stimulated
by a step change in agonist concentration. This induces an immediate
[Ca2+]i transient lasting ≈ 60 s which is followed by a [Ca2+]i plateau.
Effects on penetration of viscous medium will depend on effects exerted
potentially over 10 s of minutes, whereas initial assessment of CASA
characteristics is made 2–3min after stimulation. Assay of the rapid
[Ca2+]i transient can provide an excellent HTS of CatSper activation but
is likely to generate ‘false positives’ regarding functional motility—those
instances when the Ca2+ transient is not followed by a signiﬁcant plat-
eau. Our previous work (Alasmari et al., 2013a,b and unpublished data)
suggest that Ca2+ store mobilization downstream of CatSper activation
may be important in determining the [Ca2+]i plateau and consequent
changes in functional motility, although the factors that determine
whether this occurs are not yet clear.
CatSper channels appear to be the primary Ca2+ inﬂux pathway in
mammalian sperm (Brenker et al., 2012). By contrast, the contribution
of conventional voltage-operated Ca2+ channels to Ca2+ inﬂux is min-
imal (Zeng et al., 2013). Using patch-clamp electrophysiology and a pH-
sensitive dye, we examined the mechanism by which two of the leading
compounds (A and B) inﬂuence calcium. Both compounds A and B
affected CatSper but there was no noticeable effect on KSper. As
CatSper is partially regulated by pH we examined the effect on pH.
There was minimal effect on intracellular pH, therefore compounds A
and B are unlikely to activate CatSper via cellular alkalinisation. Both
CatSper and KSper are unique to sperm, and have been identiﬁed as
the primary ion channels in mice and humans by patch-clamp techni-
ques (Lishko et al., 2011; Strunker et al., 2011; Mansell et al., 2014). Ion
channels already represent a class of drug targets that have proven
promising for numerous neurological and cardiovascular drug discovery
applications (Bagal et al., 2013). However, as a class, ion channels
remain underexploited in drug discovery, mainly due to poor selectivity
or signiﬁcant side effect proﬁle or toxicities due to widespread tissue
distribution of ion channels, coupled with the multitude of physiological
consequences of their opening and closing. The existence of sperm-
speciﬁc ion channels may avoid these issues, which makes an argument
for this approach to drug discovery both valid and highly compelling.
What are the future practical uses of a HTS system for motile human
spermatozoa? One potential use, as suggested previously, is to screen
for compounds that can adversely affect sperm function, for example
toxic chemicals in the environment (Schiffer et al., 2014), and/or to
develop potential new targeted contraceptive approaches to deliber-
ately negatively interfere with sperm function (Carlson et al., 2009). In
these contexts, it may not be necessary to determine speciﬁc effects on
sperm motility, as an adverse effect on calcium regulation could interfere
with a plethora of other functional attributes of the human spermato-
zoon. With the notable lack of progress in male contraceptive research
and identiﬁcation of key targets (Amory, 2016) effective HTS also pre-
sents a powerful new approach. Our research strategy was to develop a
tool to screen drug discovery library compounds to identify those that
positively inﬂuence sperm function, speciﬁcally motility. Currently, we
have only screened a small (3342 compounds) ion channel library but
larger more comprehensive libraries can now be screened in a time and
resource efﬁcient way. Importantly, this will provide outputs that can
then be used as starting points for a future hit optimization programme,
and a more rigorous study of SARs, ultimately providing candidate drugs
for clinical trials. Effective HTS is a cornerstone to drug discovery and an
exciting step towards identiﬁcation of new compounds that may be
used to treat speciﬁc forms of sperm dysfunction. Further experiments
examining relevant effects of these compounds are now necessary, for
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example, their effect on human IVF possibly using sibling oocytes as an
experimental model. Critically, it is essential that experiments are done
using human spermatozoa as the entry of calcium (and/or mobilization)
into the mature human spermatozoon is very different in other mam-
mals (Kaupp and Strunker, 2017) and the relevance of animal data to
human cells is likely to be very limited.
In summary, we have developed an exciting ﬁrst step towards utiliza-
tion of HTS to drive forward drug discovery for male subfertility. This
HTS screen has successfully examined an ion channel-focussed library,
identifying compounds that increase [Ca2+]i in motile human sperm
cells from both healthy donors and, crucially, a small group of patients
undertaking IVF/ICSI. These effects are likely modulated via CatSper,
rather than pH, and positively impact on functional motility. Strategies
aimed at further characterizing sperm ion transport and the control of
speciﬁc functions that shape the unique and sophisticated behaviour of
sperm offer exciting opportunities to increase our knowledge, as well
as carrying clear translational possibilities to develop novel fertility
treatments, and new hope to millions of infertile couples worldwide.
Supplementary data
Supplementary data are available at Human Reproduction online.
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